Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data from peripheral human T cells stimulated with an anti-CD96 mAb

ABSTRACT: Expression data from peripheral human T cells stimulated with an anti-CD96 mAb

PROVIDER: PRJNA798252 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR17652343_1.fastq.gz	Fastqsanger.gz
	SRR17652343_2.fastq.gz	Fastqsanger.gz
	SRR17652344_1.fastq.gz	Fastqsanger.gz
	SRR17652344_2.fastq.gz	Fastqsanger.gz
	SRR17652345_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 22

Similar Datasets

Expression data from peripheral human T cells stimulated with an anti-CD96 mAb

Project description:The role of CD96 in human T cells is ambiguous. We demonstrated that engagement of CD96 on human T cells by antibodies provides a strong activating signal dependent on antibody isotype and cross-linking by a subset of Fcγ receptors. Here we used RNASeq profiling to analyze the gene expression programme associated with anti-CD96 mAb treatment in purified T cells isolated from the blood of healthy donors. We showed that multiple hallmarks associated with an activated T-cell signature were significantly enriched in the anti-CD96 treatment group. These included gene signatures associated with cell cycle progression, metabolic reprogramming, effector differentiation, and sustained proliferation and survival. Using pathway analysis, we identified several candidate molecules that could mediate signaling downstream of CD96.

2022-09-30 | GSE193864 | GEO

Transcription profiling of human PBMC treated with anti-CD25 mAb

Project description:CD25 monoclonal antibody binding to the alpha-chain of the Interleukin-2 (IL-2) receptor, blocks high affinity IL-2 binding thereby preventing complete T cell activation and being of ample importance in transplantation medicine and potentially the treatment of autoimmune disease. However, CD25 antibodies do not only block T cell activation but also prevent activation induced cell death (AICD) attributing a dual function to IL-2. In this study, the modulation of the genomic expression profile of human peripheral blood mononuclear cells (PBMC) with therapeutic concentrations of humanized anti-CD25 mAb was investigated. PBMC were stimulated with CD3 antibody OKT-3 together with recombinant IL-2 in the absence or presence of anti-CD25 mAb. RNA was extracted and subjected to microarray analysis on U133A microarrays (Affymetrix). The expression profile revealed the up-regulation of 62 genes and down-regulation of 38 genes by anti-CD25 mAb, respectively. Experiment Overall Design: Peripheral blood mononuclear cells (PBMC) were stimulated for 8 or 16 hrs with 100 ng/ml OKT-3 together with 100 U/ml recombinant human interleukin-2 (rhIL-2) in the absence or presence of 30 Âµg/ml anti-CD25 antibody. RNA from cells under such treatment was isolated with Trizol and subjected to microarray analysis onto human U133A microarray following the Affymetrix protocol.

2009-05-11 | E-GEOD-15928 | biostudies-arrayexpress

Expression data from human peripheral blood lymphocytes stimulated with anti-CD3 and anti-CD28 antibodies.

2013-02-25 | GSE29624 | GEO

Influence of anti-CD25 mAb on the transcriptome of activated PBMC

2009-05-02 | GSE15928 | GEO

Expression analysis of primary human monocytes stimulated with an anti-TLR10 mAb (5C2C5)

Project description:We report that engagment of TLR10 via the 5C2C5 anti-TLR10 mAb causes differential expression is a subset of inflammatory, miRNA and uncharacterized genes compared to an isotype control antibody

2017-02-17 | GSE94969 | GEO

Expression data from human peripheral blood lymphocytes stimulated with anti-CD3 and anti-CD28 antibodies.

Project description:Peripheral blood lymphocytes were separated in the Ficoll gradient and subjected for stimulation with anti-CD3 and anti-CD28 antiobodies upon time (6h, 12h and 18h). Next, total RNA was isolated and trenscriptional analysis of stimulated cells was performed. 11 total samples were analysed. Analysis was performed using samples from two healthy donors and one sample from patient. Unstimulated samples were used as a controls.

2013-02-25 | E-GEOD-29624 | biostudies-arrayexpress

Transcriptomic data of B-cell lymphoma bearing mice treated with anti-CD20/-CD27 mAb therapy

Project description:We report the single-cell RNA sequencing data obtained from BCL1 lymphoma-bearing mice treated with either isotype control, anti-CD20 mAb, anti-CD27 mAb or anti-CD20+anti-CD27 mAb together

2018-01-12 | GSE97037 | GEO

Anti-CD3 mAb treatment reshapes infiltrating T and beta cells in the islets in autoimmune diabetes

Project description:Anti-CD3 mAb delays or prevents type 1 diabetes (T1D) by modulating the immune mediated destruction of beta cells. Our findings described the reshaping of islet-infiltrating T cells and beta cells that lead to operational, but tenuous tolerance to autoimmune diabetes following anti-CD3 mAb treatment.

2025-03-24 | GSE292313 | GEO

RNAseq analysis of anti-BTLA vs control treated anti-CD3 stimulated mouse T cells or IgM stimulated mouse B cells

Project description:This dataset comprises an analysis of BTLA signaling in wild-type mouse T cells or B cells. These purified CD4+ T cells or purified B cells were stimulataed through their antigen receptors and/or Interferon receptor and costimulated with anti-BTLA mAb that activates BTLA signaling. High throughput sequencing was performed on the RNA purified from stimulated populations to characterize how BTLA signaling regulates antigen receptor and type I interferon receptor signaling in T cells and B cells.

2022-02-09 | GSE196204 | GEO

Expression data from T-cell Acute Lymphoblastic Leukemia (T-ALL) patient-derived xenograft treated with anti-CD3 mAb

Project description:T-cell acute lymphoblastic leukemia is a hematological malignancy treated by chemotherapy, with a poor prognosis. We have demonstrated that activation of the T cell receptor (TCR) by anti-CD3 antibodies has a potent anti-leukemic effect in patient-derived xenograft models (PDX) of T-ALL. Therefore, with this experiment, we aim to identify the molecular mechanisms underlying the anti-leukemic properties of the OKT3 anti-CD3 mAb in T-ALL PDX.

2024-03-19 | GSE240296 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data